Thompson Investment Management Inc. Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Thompson Investment Management Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,466 shares of the company’s stock after acquiring an additional 502 shares during the quarter. Thompson Investment Management Inc.’s holdings in Johnson & Johnson were worth $7,192,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in JNJ. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $4,071,642,000. Wellington Management Group LLP grew its stake in Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after buying an additional 3,391,657 shares during the last quarter. International Assets Investment Management LLC grew its stake in Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock worth $327,647,000 after buying an additional 2,064,175 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Johnson & Johnson during the 4th quarter worth $193,050,000. Finally, Global Assets Advisory LLC bought a new position in Johnson & Johnson during the 1st quarter worth $170,372,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Trading Down 0.2 %

Shares of NYSE JNJ traded down $0.25 during mid-day trading on Wednesday, hitting $146.94. 2,067,336 shares of the company traded hands, compared to its average volume of 7,382,193. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The stock has a market capitalization of $353.64 billion, a price-to-earnings ratio of 9.13, a PEG ratio of 2.45 and a beta of 0.53. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average of $148.13 and a two-hundred day moving average of $154.24.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.68 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.38%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.